Description
United Therapeutics Is Not Just A Tyvaso Story — Xenotransplantation Reshapes The Pipeline!
United Therapeutics Corporation reported second-quarter 2026 revenues of approximately $783 million, maintaining flat performance compared to the prior quarter but falling short of internal expectations. The company acknowledged investor concerns regarding growth acceleration and highlighted ongoing efforts to drive improved results in the latter half of the year, emphasizing momentum despite current revenue levels. Tyvaso, the company’s inhaled prostacyclin therapy, generated $453 million in revenue but experienced competitive pressures within the inhaled prostacyclin market segment. Notably, the newer Tyvaso DPI showed growth and positive momentum, supported by record patient metrics such as starts, referrals, and total patients under treatment. The company also substantially increased its sales force, doubling the team as of early July, aiming to enhance physician engagement and broaden community outreach, particularly in preparation for upcoming launches. United Therapeutics is progressing clinical and regulatory activities on multiple fronts.
